Tyme Inc. (TYME) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TYME Reports Third Quarter Fiscal 2019 Financial and Operating Results
February 11, 2019 7:31 AM ESTTYMEs novel metabolic-based investigational cancer therapy, SM-88, demonstrated encouraging results and a well-tolerated safety profile in a preliminary analysis from a Phase II study of patients with advanced pancreatic cancerTYME is in discussions with the FDA regarding pivotal trial design for third-line pancreatic cancer based on preliminary results from the TYME-88-Panc Phase II trialTYME partners with the Pancreatic Cancer Action Networks (PanCAN) Precision Promise(SM) program to advance SM-88 pivotal paths for first- and second-line treatment in patients with pancreatic cancerInitiation of investigator-sponsored Phase II trial using SM-88 as monotherapy in patients with... More
